BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ratanaphan A. A DNA repair BRCA1 estrogen receptor and targeted therapy in breast cancer. Int J Mol Sci 2012;13:14898-916. [PMID: 23203101 DOI: 10.3390/ijms131114898] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
Number Citing Articles
1 Sun HB, Wang HY, Wu B, Wang ZF, Wang LZ, Li FQ, Wu JD, Zhang LN. The inhibitory effects of cisplatin-radiation combination treatment on malignant osteosarcoma MG-63 cells and BRCA1-p53 pathways are more efficient than single treatments. Oncol Lett 2019;18:6385-96. [PMID: 31807162 DOI: 10.3892/ol.2019.11019] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
2 Akhtar A, Danish M, Asif A, Arshad MN, Asiri AM. DNA binding and cleavage, BRCA1 gene interaction, antiglycation and anticancer studies of transition metal complexes of sulfonamides. Mol Divers 2022. [PMID: 35182295 DOI: 10.1007/s11030-021-10366-5] [Reference Citation Analysis]
3 Leesakul N, Kullawanichaiyanan K, Mutić S, Guzsvány V, Nhukeaw T, Ratanaphan A, Saithong S, Konno T, Sirimahachai U, Promarak V. A photoactive iridium(III) complex with 3-methyl-2-phenyl pyridine and 1,1-bis(diphenylphosphino)methane: Synthesis, structural characterization and cytotoxicity in breast cancer cells. Journal of Coordination Chemistry 2021;74:2380-94. [DOI: 10.1080/00958972.2021.1949585] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Spugnesi L, Gabriele M, Scarpitta R, Tancredi M, Maresca L, Gambino G, Collavoli A, Aretini P, Bertolini I, Salvadori B, Landucci E, Fontana A, Rossetti E, Roncella M, Naccarato GA, Caligo MA. Germline mutations in DNA repair genes may predict neoadjuvant therapy response in triple negative breast patients. Genes Chromosomes Cancer 2016;55:915-24. [PMID: 27328445 DOI: 10.1002/gcc.22389] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
5 Savage RS, Yuan Y. Predicting chemoinsensitivity in breast cancer with 'omics/digital pathology data fusion. R Soc Open Sci 2016;3:140501. [PMID: 26998311 DOI: 10.1098/rsos.140501] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
6 Wozniak K, Krupa R, Synowiec E, Morawiec Z. Polymorphism of UBC9 gene encoding the SUMO-E2-conjugating enzyme and breast cancer risk. Pathol Oncol Res 2014;20:67-72. [PMID: 23873416 DOI: 10.1007/s12253-013-9659-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
7 Rajan A, Nadhan R, Latha NR, Krishnan N, Warrier AV, Srinivas P. Deregulated estrogen receptor signaling and DNA damage response in breast tumorigenesis. Biochim Biophys Acta Rev Cancer 2021;1875:188482. [PMID: 33260050 DOI: 10.1016/j.bbcan.2020.188482] [Reference Citation Analysis]
8 Nhukeaw T, Temboot P, Hansongnern K, Ratanaphan A. Cellular responses of BRCA1-defective and triple-negative breast cancer cells and in vitro BRCA1 interactions induced by metallo-intercalator ruthenium(II) complexes containing chloro-substituted phenylazopyridine. BMC Cancer 2014;14:73. [PMID: 24507701 DOI: 10.1186/1471-2407-14-73] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 2.9] [Reference Citation Analysis]
9 Chitrala KN, Nagarkatti M, Nagarkatti P, Yeguvapalli S. Analysis of the TP53 Deleterious Single Nucleotide Polymorphisms Impact on Estrogen Receptor Alpha-p53 Interaction: A Machine Learning Approach. Int J Mol Sci 2019;20:E2962. [PMID: 31216622 DOI: 10.3390/ijms20122962] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
10 Liang S, Peng X, Li X, Yang P, Xie L, Li Y, Du C, Zhang G. Silencing of CXCR4 sensitizes triple-negative breast cancer cells to cisplatin. Oncotarget 2015;6:1020-30. [PMID: 25544759 DOI: 10.18632/oncotarget.2741] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 3.3] [Reference Citation Analysis]
11 Xu L, Shen JM, Qu JL, Song N, Che XF, Hou KZ, Shi J, Zhao L, Shi S, Liu YP, Qu XJ, Teng YE. FEN1 is a prognostic biomarker for ER+ breast cancer and associated with tamoxifen resistance through the ERα/cyclin D1/Rb axis. Ann Transl Med 2021;9:258. [PMID: 33708885 DOI: 10.21037/atm-20-3068] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
12 Mohamad Hanif EA, Shah SA. Overview on Epigenetic Re-programming: A Potential Therapeutic Intervention in Triple Negative Breast Cancers. Asian Pac J Cancer Prev 2018;19:3341-51. [PMID: 30583339 DOI: 10.31557/APJCP.2018.19.12.3341] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]